🟢 Roivant Sciences is trading 10.5% up in pre-market after brepocitinib met primary endpoints in both trials

Roivant Sciences is trading at $38.60, up 10.54%, after positive Phase 3 results for brepocitinib in non-infectious uveitis.

• CLARITY-1 and CLARITY-2 met their primary and key secondary endpoints.
• At Week 48, 62% of patients on brepocitinib achieved steroid-free quiescence, versus 20% on placebo.